Snap cannot keep up with the Kardashians because its stock loses $1 billion market value after Kylie Jenner tweets about her decision to leave Snapchat.

Monica McNeil

2018-02-19 08:39:00 Mon ET

Snap cannot keep up with the Kardashians because its stock loses market value 7% or $1 billion after Kylie Jenner tweets about her decision to leave Snapchat.

The root cause of this rare incidence may be Snap's recent redesign, or Jenner's newfound motherhood. The former can be a real concern that her 25 million Twitter followers share in numerous replies. These empathetic users aggravate this deep concern about Snap's recent redesign and thereby echoes ambivalent Wall Street investor sentiments.

Several Wall Street stock analysts point out that it can be more difficult for Snap to monetize the Snapchat business model in contrast to ad-income-driven Facebook, Google, and Twitter. In recent times, Snap initiates some smart strategic moves to draw a clear line between social interactions and media posts and video streams. In fact, Snap needs to manage this interim transition well as celebrity influencers such as Kylie Jenner are an essential source of high-quality content in the Snap recipe for success. With 25 million Twitter followers, Jenner carries a great deal of social influence over millennials.

In terms of demographic attributes, the typical Snapchat user is between 18 and 24 years old and tends to have much shorter attention span.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Trumpism may now become the new populist world order of economic governance.

Monica McNeil

2018-07-30 11:36:00 Monday ET

Trumpism may now become the new populist world order of economic governance.

Trumpism may now become the new populist world order of economic governance. Populist support contributes to Trump's 2016 presidential election victory

+See More

President Trump picks David Malpass to run the World Bank to curb international multilateralism.

Rose Prince

2019-02-07 07:25:00 Thursday ET

President Trump picks David Malpass to run the World Bank to curb international multilateralism.

President Trump picks David Malpass to run the World Bank to curb international multilateralism. The Trump administration seems to prefer bilateral negotiat

+See More

The Economist highlights a trifecta of plausible explanations for better economic fortunes during the current Trump administration.

Chanel Holden

2018-08-27 09:35:00 Monday ET

The Economist highlights a trifecta of plausible explanations for better economic fortunes during the current Trump administration.

President Trump and his Republican senators and supporters praise the recent economic revival of most American counties. The Economist highlights a trifecta

+See More

Disney acquires 21st Century Fox in a $52 billion landmark deal.

Amy Hamilton

2017-12-15 07:42:00 Friday ET

Disney acquires 21st Century Fox in a $52 billion landmark deal.

Disney acquires 21st Century Fox in a $52 billion landmark deal. This deal has a total value of about $66 billion while Disney assumes $14 billion of Fox

+See More

Corporate ownership governance theory and practice

Monica McNeil

2022-04-25 10:34:00 Monday ET

Corporate ownership governance theory and practice

Corporate ownership governance theory and practice  The genesis of modern corporate governance and ownership studies traces back to the seminal work

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More